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Introduction
Research Design
Conclusions
Of the many proteins that PKCβII phosphorylates, for the purposes of this study, we believe 
NOX-2 phosphorylation is a key pathway in the ROS mediated damage in MI/R injury.  
Thus, we hypothesize that myr-PKCβII- will reduce infarct size and improve post-
reperfused cardiac function as compared to non-drug treated controls, whereas myr-
PKCβII+ treated hearts will not improve these parameters. 
Results
Hypothesis
Figure  1. . Schematic representation 
of PKCβII mediated activation of 
mitochondrial reactive oxygen 
species (ROS) and NADPH oxidase 
superoxide (O2-) release and 
decreased NO release from eNOS in 
MI/R (adapted from [5,6]). MI/R 
induces cytokine receptor activation 
leading to activation of PKC βII via 
diacylglycerol (DAG). Activated 
PKCβII increases ROS and O2-
release from damaged mitochondria 
and NADPH oxidase, respectively, 
and decreases eNOS activity.  It also 
stimulates mitochondrial p66Shc 
protein, a component in the pathway 
resulting in opening of the 
mitochondrial permeability transition 
pore (PTP), which in turn leads to 
release of proapoptotic factors into 
the cytosol to further promote tissue 
injury during reperfusion.   
Heart disease remains the leading cause of death in adults in the United States and 
worldwide, with coronary artery disease being the most common form that often leads to a 
myocardial infarction.  While rapid restoration of coronary blood flow is crucial to 
preserving cardiac tissue function, it also results in an additional insult known as 
myocardial ischemia/reperfusion (MI/R) injury. MI/R injury may be attenuated by 
inhibiting the generation of reactive oxygen species (ROS) upon cardio-angioplasty 
following a heart attack. Protein kinase C beta II (PKCβII) generates ROS during 
reperfusion via cytokine receptor activation (Figure 1) (1).  Activated PKCβII (via Ca2+
and second messenger diacylgylcerol) binds to its selective receptor for activated C kinase 
(RACK). RACK enhances PKCβII translocation to the cell membrane and its interaction 
with substrates, like NADPH oxidase (NOX-2) (2). PKCβII phosphorylates and activates 
NOX-2 which then generates ROS (Figure 2) (3,4).
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Figure 2. Schematic representation of PKCβII peptides. PKCβII+ and PKCβII- both bind to the Ca2+
binding domain within the RACK binding site (i.e., C2-4 region;) of PKCβII to regulate its translocation
to the cell membrane (top; Adapted from [3]). PKCβII+ mechanism of action is to increase PKCβII
translocation to the cell membrane via RACK binding and its interaction with substrates, like NOX-2,
while PKCβII- inhibits that interaction (bottom; Adapted from [2]).
Table 1.  Initial and final cardiac function values and infarct size for control, myr-PKCβII+/- MI/R studies; *p<0.05, **p<0.01 vs. 
non-drug treated controls; #p<0.05, ##p<0.01 vs. myr-PKCβII+.  Representative sections shown  are both sides of a 2mm mid-wall 
section for each MI/R study group. +dP/dt max = contractility, -dP/dt min = relaxation, LVDP = left ventricular developed pressure, 
LVESP = left ventricular end systolic pressure, LVEDP = left ventricular end diastolic pressure.  
Inhibition of tissue NOX-2 attenuates inflammation mediated vascular injury seen in various 
diseases, including diabetes and myocardial infarction (4).  Previously, a myristoylated (myr-) 
selective PKCβII peptide inhibitor (N-myr-SLNPEWNET; myr-PKCβII-) was found to dose 
dependently inhibit superoxide (SO) release and MI/R injury via the mechanism depicted in 
Figure 2 (3, 6, 7).  Myristoylation of peptides is known to potentiate their entry into the cell 
via simple diffusion through the cell membrane to affect PKC activity (8).  However, the 
effect of myr-PKCβII peptide activator (N-myr-SVEIWD; myr-PKCβII+) on MI/R injury has 
not been studied (9). 
Statistical Analysis
All data in the text, figures, and table are presented as means ± S.E.M. The data were 
analyzed by ANOVA using the Fisher’s PLSD test. Probability values of <0.05 are 
considered to be statistically significant.
Male Sprague-Dawley rats (~300g, Charles River, Springfield, MA) were anesthetized with 
I.P. pentobarbital (60mg/kg) and anticoagulated with 1000U of heparin. The heart was then 
removed and placed on the perfusion needle of the Langendorff apparatus.  A pressure 
transducer was placed into the left ventricle to measure cardiac function, as previously 
described (6,7).  
A schematic of the MI/R protocol is depicted below:   
Baseline 
(15min.)
Ischemia 
(30min.)
Reperfusion 
(50min.)
TTC 
staining 
myr-PKCβII+/-
(20μM) first 
5min.
Cardiac Function and 
Infarct Size Indices
Control (n= 9) PKCβ Inhibitor (n=8) PKCβ Activator (n=9)
Initial Flow (mL/min) 20±2 17±1 18±2
Final Flow (mL/min) 10±1 10±1 11±2
Initial +dP/dtmax
(mmHg/sec)
2428±81 2316±48 2430±65
Final +dP/dtmax
(mmHg/sec)
906±137 1585±165**## 989±161
Initial -dP/dtmin
(mmHg/sec)
-1685±87 -1637±46 -1630±76
Final -dP/dtmin
(mmHg/sec)
-855±118 -1048±121*# -814±103
Initial LVDP (mmHg) 96±3 89±2 91±3
Final LVDP (mmHg) 48±9 67±7*## 43±7
Initial LVESP (mmHg) 105±4 98±2 98±3
Final LVESP (mmHg) 106±5 104±5 104±3
Initial LVEDP (mmHg) 9±1 8±1 7±1
Final LVEDP (mmHg) 58±5 37±7**## 58±4
Initial Heart Rate 
(BPM)
273±5 276±8 280±10
Final Heart Rate 
(BPM)
258±8 247±5 246±8
Infarct Size (%) 26±5 14±3* 25±3
Representative 
Sections
At the end of the reperfusion period, all hearts were frozen at -20 oC for 30 min, sectioned 
into 2mm slices and incubated at 37oC in 1% triphenyltetrazolium chloride (TTC). The 
percentage between dead heart tissue (i.e., unstained) weight to total heart tissue weight 
was calculated for infarct size.
N-Myr-SLNPEWNET
Figure 3. Time course of left ventricular developed pressure (LVDP) for control, myr-PKCβII+/- MI/R studies. 
Myr-PKCβII- treated hearts showed a trend to improve LVDP after the first five minutes of reperfusion and this 
trend was exhibited throughout the 50 minute reperfusion time course.  This was significantly different from both 
control and myr-PKCβII+ treated hearts during the reperfusion period. *p<0.05 vs. non-drug treated controls, 
##p<0.01 vs. myr-PKCβII+. 
Infarct size
Myr-PKCβII- treated hearts had significantly reduced infarct size compared to controls. We 
believe there was no significant difference between myr-PKCβII- and myr-PKCβII+ because 
NOX-2 mediated ROS generation during reperfusion may be maximally activated by tissue 
cytokines and further stimulation by myr-PKCβII+ does not result in additional tissue injury. 
Cardiac function
Myr-PKCβII- improved post-reperfused cardiac function (vs. both control and myr-PKCβII+).  
The significant improvement in final post-reperfusion LVDP in myr-PKCβII- treated hearts is 
attributed to the significant reduction in final LVEDP values (i.e. ~37mmHg) compared to 
control and myr-PKCβII+ hearts (i.e. ~58mmHg), and is reflected in the significant restoration 
of the final maximal rate of contractility (+dP/dtmax) and relaxation (-dP/dtmin). 
These results suggest that: 1) Inhibition of myocardial tissue NOX-2 activity may be the 
principal pathway through which myr-PKCβII- mediates its cardio-protective effects in MI/R 
injury. 2) Treatment with myr-PKCβII- would be an effective strategy to limit MI/R injury in 
heart attack patients upon reperfusion via fibrinolytic therapy, angioplasty or coronary artery 
bypass surgery.
